| Literature DB >> 29374391 |
Marzia Pucci1,2,3, Pablo Reclusa Asiáin1,2, Elena Duréndez Sáez1,4,5, Eloisa Jantus-Lewintre4,5,6, Mahafarin Malarani1,2, Shahanavaj Khan7,8, Simona Fontana3, Aung Naing9, Francesco Passiglia2, Luis E Raez10, Christian Rolfo11,12, Simona Taverna13,14.
Abstract
Tumor-derived extracellular vesicles (EVs) have a pleiotropic role in cancer, interacting with target cells of the tumor microenvironment, such as fibroblasts, immune and endothelial cells. EVs can modulate tumor progression, angiogenic switch, metastasis, and immune escape. These vesicles are nano-shuttles containing a wide spectrum of miRNAs that contribute to tumor progression. MiRNAs contained in extracellular vesicles (EV-miRNAs) are disseminated in the extracellular space and are able to influence the expression of target genes with either tumor suppressor or oncogenic functions, depending on both parental and target cells. Metastatic cancer cells can balance their oncogenic potential by expressing miRNAs with oncogenic function, whilst exporting miRNAs with tumor suppressor roles out of the cells. Importantly, treatment of cancer cells with specific natural and chemical compounds could induce the elimination of miRNAs with oncogenic function, thereby reducing their aggressiveness. In this review, we discuss the mechanisms by which EV-miRNAs, acting as miRNAs with oncogenic or tumor suppressor functions, could contribute to cancer progression.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29374391 DOI: 10.1007/s11523-018-0551-8
Source DB: PubMed Journal: Target Oncol ISSN: 1776-2596 Impact factor: 4.493